drugset / Trial / NCT06782594

A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction

NCT06782594

Phase 2 Recruiting 150 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study.

Timeline

Start
2024-10-18
Primary completion
2025-06
Completion
2025-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mosapride Small molecule 4 mg Intravenous
Subject Mosapride Small molecule 8 mg Intravenous